Incyte Corporation Reports 2014 Third-Quarter Financial Results And Updates Shareholders On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reported 2014 third-quarter financial results, including revenue from Jakafi® (ruxolitinib). The Company highlighted the strength in Jakafi sales in the U.S. as well as the recognition of two significant milestone payments from Novartis related to Jakavi® (ruxolitinib), totaling $85 million. The Company outlined its progress in recruiting multiple clinical trials, including those investigating its JAK inhibitors in solid tumors and its IDO1 inhibitor in combination with other immuno-oncology agents.

Help employers find you! Check out all the jobs and post your resume.